|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
Cambridge Healthtech Institute's Molecular Display | ||||||||||||||||
January 28, 2003 | ||||||||||||||||
Cambridge Healthtech Institute, Hyatt Regency Cambridge, 575 Memorial Drive, Cambridge, MA 02139 May 12-13, 2003 NEW TECHNOLOGIES AND TARGET SELECTION Cell-Based Systems for Protein Engineering High-Diversity Libraries for Rapid Protein Optimization Monobodies: Small Antibody Mimics Phage-Based Electronic and Magnetic Materials USE OF PHAGE DISPLAY TO DISCOVER SMALL MOLECULES APPLICATIONS IN PROTEOMICS APPLICATION IN NOVEL THERAPEUTICS AND DIAGNOSTICS POST-CONFERENCE TUTORIAL Phage display of peptide and protein libraries is a powerful tool for identifying compounds that recognize and bind to targets that have been identified. These repertoires of proteins and peptides include enzymes and antibodies, which have interest as drug targets. Phage systems are used for the detection of protein-ligand interactions and for improving binding affinities. The diversity of display methodologies that exist (ribosome, yeast, phage, bacterial, antibody) offers a variety of capabilities in panning for affinity interactions. Alternative display systems offer the opportunity to address issues of expression biases that exist with phage display and to explore the possibility of creating compounds of small molecular weight, greater diversity, and druglike properties. Phage display can be used to identify biomarkers of disease in prostate cancer, cardiovascular disease, and angiogenesis. The peptides are capable of homing to specific pathways and targets within those pathways. By generating the proteins expressed from cDNA libraries, display methodologies can provide a direct link between phenotype and genotype.
|
||||||||||||||||
Organized by: | Cambridge Healthtech Institute | |||||||||||||||
Invited Speakers: | Dr. Robert F. Balint, KaloBios, Inc. Dr. Angela Belcher, Massachusetts Institute of Technology Mr. Steven E. Cwirla, XenoPort Inc. Dr. Sven Klussmann, NOXXON Pharma AG Dr. Shohei Koide, The University of Chicago Dr. Elias Lazarides, Targeted Molecules Corporation (TMC) Mr. Hening Lin, Columbia University Dr. Lee Makowski, Argonne National Laboratory Dr. Michael McPherson, Phylos, Inc. Dr. Renata Pasqualini, M.D. Anderson Cancer Center, University of Texas Dr. Edward F. Patz, Jr., Duke University Medical Center Dr. Henrik Pedersen, Nuevolution A/S, Denmark Dr. Christopher P. Rusconi, Duke University Medical Center Dr. Aaron Sato, Dyax Corp. Dr. Sachdev Sidhu, Genentech Inc. Dr. Merilyn Sleigh, Evogenix Pty Ltd. Dr. Michael A. Tainsky, Wayne State University Dr. Michael B. Yaffe, Massachusetts Institute of Technology Dr. Ping Zhong, Abmaxis Inc. PRE-CONFERENCE TUTORIAL |
|||||||||||||||
Deadline for Abstracts: | April 4, 2003 | |||||||||||||||
Registration: | Available Online Call: 617-630-1300/Fax: 617-630-1325 e-mail: chi@healthtech.com | |||||||||||||||
E-mail: | eeskedal@healthtech.com | |||||||||||||||
Posted by: | elaine eskedal | |||||||||||||||
Host: | wks152.healthtech.com | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |